Literature DB >> 19719780

On the mechanism of the persistent action of salmeterol: what is the current position?

R A Coleman1.   

Abstract

The mechanism of the long duration of action of salmeterol at beta(2)-adrenoceptors has long been a matter of debate, and is still unresolved. Szczuka and colleagues have both summarized the position to date and suggested a new mechanistic contender, receptor rebinding. Despite this, they still do not come to any clear conclusion. Much of the literature data that they have drawn upon appears contradictory, and mathematical models are inevitably flawed by the questionable validity of key values applied to them. Although the issue will undoubtedly eventually be resolved, it will probably require investigators to apply carefully designed studies on simple experimental systems such as isolated membranes or cultured cells. Only then should studies be extended to more complex systems such as isolated preparations of airways smooth muscle, where tissue bulk inevitably presents a complicating factor, particularly where relatively lipophilic compounds are concerned.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19719780      PMCID: PMC2795233          DOI: 10.1111/j.1476-5381.2009.00370.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

Review 1.  The 1990 Lilly Prize Lecture. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other beta-adrenoceptor agonists.

Authors:  D Jack
Journal:  Br J Clin Pharmacol       Date:  1991-05       Impact factor: 4.335

2.  In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.

Authors:  Cliff Battram; Steven J Charlton; Bernard Cuenoud; Mark R Dowling; Robin A Fairhurst; David Farr; John R Fozard; Juliet R Leighton-Davies; Christine A Lewis; Lorraine McEvoy; Robert J Turner; Alexandre Trifilieff
Journal:  J Pharmacol Exp Ther       Date:  2006-01-24       Impact factor: 4.030

Review 3.  Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists.

Authors:  R A Coleman; M Johnson; A T Nials; C J Vardey
Journal:  Trends Pharmacol Sci       Date:  1996-09       Impact factor: 14.819

4.  Extent of salmeterol-mediated reassertion of relaxation in guinea-pig trachea pretreated with aliphatic side chain structural analogues.

Authors:  A Bergendal; A Lindén; B E Skoogh; M Gerspacher; G P Anderson; C G Löfdahl
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 5.  Why are long-acting beta-adrenoceptor agonists long-acting?

Authors:  G P Anderson; A Lindén; K F Rabe
Journal:  Eur Respir J       Date:  1994-03       Impact factor: 16.671

6.  Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol.

Authors:  A Szczuka; M Wennerberg; A Packeu; G Vauquelin
Journal:  Br J Pharmacol       Date:  2009-07-07       Impact factor: 8.739

7.  Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase.

Authors:  A Teschemacher; H Lemoine
Journal:  J Pharmacol Exp Ther       Date:  1999-03       Impact factor: 4.030

8.  QSAR and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonists.

Authors:  Rupert P Austin; Patrick Barton; Roger V Bonnert; Roger C Brown; Peter A Cage; David R Cheshire; Andrew M Davis; Iain G Dougall; Francis Ince; Garry Pairaudeau; Alan Young
Journal:  J Med Chem       Date:  2003-07-17       Impact factor: 7.446

9.  Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers.

Authors:  D G Rhodes; R Newton; R Butler; L Herbette
Journal:  Mol Pharmacol       Date:  1992-10       Impact factor: 4.436

  9 in total
  12 in total

1.  Roles of affinity and lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth muscle preparations.

Authors:  R L Jones; D F Woodward; J W Wang; R L Clark
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 2.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 3.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 4.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

Review 5.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

6.  GPCR theme editorial.

Authors:  G Milligan; J C McGrath
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

7.  Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists.

Authors:  David A Sykes; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

8.  'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.

Authors:  Georges Vauquelin; David Hall; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

Review 9.  Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.

Authors:  Georges Vauquelin
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

10.  Development of Inhaled GABAA Receptor Modulators to Improve Airway Function in Bronchoconstrictive Disorders.

Authors:  Nicolas M Zahn; M S Rashid Roni; Gene T Yocum; Michelle J Meyer; Daniel A Webb; Md Yeunus Mian; James M Cook; Douglas C Stafford; Charles W Emala; Leggy A Arnold
Journal:  ACS Pharmacol Transl Sci       Date:  2022-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.